Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27711463 | 1.00 | HRH3 (0.48) | HRH3KDM4EMAOBHRH2HRH1 | |
| Bromide SCHEMBL738069 | 0.98 | HRH3 (0.47) | HRH3KDM4EMAOBHRH2HRH1 | |
| Bromide SCHEMBL736690 | 0.90 | KDM4E (0.43) | HRH3KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL9374424 | 0.88 | HRH3 (0.53) | HRH3KDM4EMAOBHRH2HRH1 | |
| SCHEMBL205774 | 0.82 | HRH3 (0.49) | HRH3KDM4EMAOBALDH1A1LMNA | |
| SCHEMBL12513823 | 0.81 | BCHE (0.55) | HRH3MAOB | |
| SCHEMBL7170601 | 0.81 | HRH3 (0.48) | HRH3KDM4EMAOBHRH2HRH1 | |
| SCHEMBL5837843 | 0.81 | HRH3 (0.55) | HRH3KDM4EMAOBHRH2HRH1 | |
| SCHEMBL2114687 | 0.81 | HRH3 (0.48) | HRH3KDM4EHRH2HRH1ALDH1A1 | |
| SCHEMBL15101577 | 0.81 | HRH3 (0.65) | HRH3KDM4EMAOBHRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101228127-B | Piperidine derivatives | BANYU PHARMA CO LTD | 2012-05-16 | — | — | CN | disclosed |
| US-7960394-B2 | 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| CN-1960977-B | Quinazoline derivative | BANYU PHARMA CO LTD | 2010-07-21 | — | — | CN | disclosed |
| US-20080275069-A1 | Quinazoline Derivative | MSD K.K. (JP) | 2008-11-06 | — | — | US | disclosed |
| CN-101228127-A | Novel Piperidine Derivatives | BANYU PHARMA CO LTD (JP) | 2008-07-23 | — | — | CN | disclosed |
| CN-1960977-A | Quinazoline derivative | BANYU PHARMA CO LTD (JP) | 2007-05-09 | — | — | CN | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275069-A1 | Quinazoline Derivative | HRH3, HRH4, HRH2 | HRH3 1/4885KDM4E 3385/4885MAOB 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.